Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like What Biogen CFO's Departure Means for Company's M&A Strategy June 14, 2017 Celgene Bangs Out Deal Worth $775 Million for Kendall Square Startup Delinia January 25, 2017 Why This Bay Area Biotech Could be a Cash Cow for Investors September 10, 2017